AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
£140.34 +52.00 (+0.37%)
As of 12:37 PM Eastern

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
1
Buy
6

Based on 7 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for AZN.

Consensus Price Target

£155.50
According to the 7 analysts' twelve-month price targets for AstraZeneca, the average price target is £155.50. The highest price target for AZN is £178, while the lowest price target for AZN is £120. The average price target represents a forecasted upside of 10.80% from the current price of £140.34.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
11/16/25 to 11/16/26
1 Month Ago
10/17/25 to 10/17/26
3 Months Ago
8/18/25 to 8/18/26
1 Year Ago
11/16/24 to 11/16/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£155.50£153.57£152.17£138
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaHealthcare Companies
Consensus Rating Score
2.86
2.32
Consensus RatingModerate BuyHold
News Sentiment Rating
Neutral News

See Recent AZN News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/6/2026
Deutsche Bank logo
Deutsche Bank
3 of 5 stars
 Boost TargetHold£117 ➝ £120-14.98%
10/30/2026 Reiterated RatingBuy£175+25.94%
10/7/2026
Berenberg Bank logo
Berenberg Bank
3 of 5 stars
 Reiterated RatingBuy£175+46.15%
9/8/2026 Initiated CoverageOutperform£145+22.59%
7/28/2026 Boost TargetBuy£175 ➝ £178+39.50%
1/16/2026 Reiterated RatingBuy
1/15/2026 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:16 PM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 13, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • Strong Q3 2026 financial performance with revenue of $16.21 billion, up 7% year over year, and earnings per share more than doubling Wall Street estimates, demonstrating robust execution and profitability.
  • Significant pipeline potential with the CEO indicating that upcoming drug trial readouts in 2027 could represent more than $20 billion in potential value, supporting long-term growth and justifying the current valuation.
  • Strategic cost management through a $1.5 billion savings program aimed at redirecting resources toward the drug-development pipeline, which could improve operating leverage and support future product launches.
  • Positive analyst sentiment with a consensus rating of Moderate Buy and a consensus price target of £153.57, reflecting confidence in the company's earnings and pipeline prospects from multiple research firms.
  • Current stock price of $13,982.00, which is below the consensus price target, suggesting potential upside for investors as the stock has recently crossed above its 200-day moving average, indicating a positive technical trend.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • Generic competition for Farxiga is weighing on results, although stronger oncology sales are currently offsetting the impact, posing a risk to future revenue growth in the cardiovascular, renal, and metabolism therapy area.
  • Recent reports of eliminating 600 US sales positions to fund the pipeline, which could indicate operational challenges or a need for significant cost-cutting measures to maintain financial health.
  • Deutsche Bank has a hold rating with a price target of £120, which is below the current stock price, suggesting that some analysts see limited upside potential or higher risk in the near term.
  • High debt-to-equity ratio of 64.10, which could limit the company's financial flexibility and increase vulnerability to economic downturns or rising interest rates.
  • Recent stock price volatility, with the stock hitting a 52-week low of $11,404.00 and a 52-week high of $15,732.00, indicating significant price swings and potential uncertainty in the market's perception of the company's value.

AZN Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £155.50, with a high forecast of £178 and a low forecast of £120.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 10.80% based on their 12-month stock forecasts.

Over the previous 90 days, AstraZeneca's stock had 1 upgrade by analysts.

AstraZeneca has been rated by research analysts at Berenberg Bank, Deutsche Bank, Jefferies Financial Group, and Royal Bank Of Canada in the past 90 days.

Analysts like AstraZeneca more than other "healthcare" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how AZN compares to other companies.


MarketBeat monitors more than a dozen sources for AstraZeneca analyst ratings, with the most recent rating issued on 11/6/2026.
From Our Partners